

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**202293Orig1s024**

**OFFICER/EMPLOYEE LIST**

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** April 28, 2021

**TO:** Administrative file for NDA 202293/S-024

**FROM:** Sabry Soukehal, RAC, Regulatory Health Project Manager  
Office of Regulatory Operations – Division of Regulatory Operations for  
Cardiology, Hematology, Endocrinology, and Nephrology for the Division of  
Cardiology and Nephrology

**SUBJECT:** Officer/Employee List for NDA 202293/S-024

**APPLICATION/DRUG:** NDA 202293/S-024, FARXIGA (dapagliflozin) Tablets

The following officers or employees of FDA participated in the decision to approve this efficacy supplement and consented to be identified on this list:

Aidoo, Mariette  
Archdeacon, Patrick  
Condarco, Tania  
Dong, Zedong  
Earp, Justin  
Fromm, Edward  
Houstoun, Monika  
Koh, William  
McDowell, Tzu-Yun  
Mehta, Hina  
Mills, Sharon  
Mistry, Kirtida  
Monteleone, Michael  
Patel, Zarna  
Raghavachari, Ramesh  
Rothmann, Mark  
Savani, Meena  
Smith, Kimberly  
Soukehal, Sabry  
Stockbridge, Norman  
Thompson, Aliza  
Unger, Ellis  
Yanoff, Lisa

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

SABRY SOUKEHAL  
04/28/2021 07:02:33 AM

¶